A subset of patients who undergo curative surgery for localized clear cell renal cell carcinoma (ccRCC) will experience early or late recurrence. Tumor viability depends on protein synthesis via the eukaryotic initiation factor (eIF)4E-binding protein 1 (4EBP1/eIF4E) axis. Activation levels of the axis in ccRCC tissues could differentially affect tumor recurrence and the timing of recurrence after curative nephrectomy. Background: The objective was to explore the predictive markers of late recurrence (LR) > 5 years after curative nephrectomy for renal cell carcinoma (RCC). Patients and Methods: We retrospectively examined the data from 303 patients with localized clear cell RCC treated surgically at our institution from 1993 to 2011. Activation of the eukaryotic initiation factor (eIF)4E-binding protein 1 (4EBP1)/eIF4E axis at the mammalian target of rapamycin complex 1 (mTORC1) was evaluated in the tumor specimens. Weak, intermediate, and strong immunohistochemistry staining grades were defined for 4EBP1, phosphorylated 4EBP1, and eIF4E. The effects of clinicopathologic factors and activation level grades on tumor recurrence were analyzed using multivariate Cox regression models. To validate the present findings, we investigated clinical data from The Cancer Genome Atlas and protein/phosphoprotein data from corresponding patients from The Cancer Proteome Atlas. Results: Of the 303 patients, 31 and 16 patients developed early recurrence (ER, 5 years) and LR, respectively. The activation levels were comparable among the subcategories of pathologic TN stage, Fuhrman grade, and microvascular and capsular invasion. Pathologic stage ! T1b, Fuhrman grade 3/4, and an intermediate or strong activation level correlated significantly with overall recurrence and ER. Strong activation of the axis and pathologic stage ! T1b were identified as independent predictors of LR. Only 2 patients with weak activation experienced recurrence (1 each with ER and LR). Similar results were confirmed by the analyses of The Cancer Genome Atlas and The Cancer Proteome Atlas data. Conclusion: The activation level of the axis in RCC tissues could independently predict for recurrence and differentially affect the timing of recurrence.
Introduction
Renal cell carcinoma (RCC) is the most common malignant tumor of the kidney.
1,2 Clear cell RCC (ccRCC), constituting w80% of RCC cases, is more aggressive, with greater rates of recurrence, metastasis, and mortality, compared with papillary and chromophobe RCC. 1, 2 According to a recent nationwide largescale study in Japan, 3 the 5-year overall survival (OS) rate for stage I, II, III, and IV RCC was 94.8%, 90.2%, 78.8%, and 39.6%, respectively, compatible with findings from other reports. 2 In general, the Distant metastases will develop in 20% to 35% and local recurrence in 2% to 5% of patients. 2 The median time to recurrence has been within 1 to 2 years (< 3 years) after the initial surgery. 5 In contrast, it has been reported that 6% to 12% of patients will experience late recurrence (LR) > 5 years after initial nephrectomy. 6, 7 Thus, LR is not a rare event for RCC; however, no standard algorithms for medical follow-up protocols > 5 years after curative surgery have been established. 1, 5 In many cancers, including ccRCC, the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin complex 1 (mTORC1), and Ras/MEK/ERK (extracellular signal-regulated kinase) pathways are aberrantly activated and contribute to oncogenesis, proliferation, invasion, and metastasis. 8 Eukaryotic initiation factor (eIF) 4E is released from eIF4E-binding protein 1 (4EBP1) when 4EBP1 is hyperphosphorylated by mTORC1 activation. The eIF4E plays central roles in cap-dependent mRNA translation, downstream of the 2 signaling pathways. 8, 9 In ccRCC, frequent inactivation of the von Hippel-Lindau (VHL) gene and aberrant activation of the PI3K/Akt/mTORC1 pathway contribute to overexpression of hypoxia-inducible factor (a transcription factor controlling expression of 500-1000 key genes 8, 10 ) by protecting hypoxia-inducible factor from ubiquitination and subsequent degradation by VHL proteins and proteasomes, respectively. 10 Numerous reports have identified genes, intracellular signaling pathways, and target molecules that can regulate tumor behavior, as potential prognostic biomarkers in localized ccRCC. 9, [11] [12] [13] Sixteen biomarkers involved in angiogenesis, cell growth/division, immune response, and inflammation were reported to better predict for RFS in patients with localized RCC after surgery compared with use of the Mayo Clinic Stage, Size, Grade, and Necrosis score. 13 However, the subcellular mechanism leading to LR after curative nephrectomy is unclear.
In the present study, we investigated the intracellular and clinicopathologic factors to predict for ER and LR (> 5 years) after curative surgery for localized ccRCC, stratifying the activation levels of the 4EBP1/eIF4E axis, which centrally regulates protein synthesis leading to malignant behavior.
Patients and Methods

Patient Population and Clinical Data Collection
We retrospectively examined the medical record archives of consecutive patients who had undergone curative surgery for localized ccRCC (pathologic T [pT]1-pT4N0M0) at Yamagata University Hospital from 1993 to 2011. The inclusion criteria were as follows: (1) a pathologic diagnosis of ccRCC using resected specimens obtained by radical or partial nephrectomy; and (2) the availability of formalin-fixed paraffin-embedded (FFPE) specimens. The exclusion criteria were as follows: (1) genetic disorders increasing the risk of ccRCC such as VHL disease; (2) the existence of synchronous bilateral ccRCC; and (3) administration of molecular-targeted drugs for neoadjuvant and/or adjuvant therapy. Finally, 303 Japanese patients with localized ccRCC were eligible, and the clinical and pathologic data were collected from the patients' medical records.
ER and LR were defined as ccRCC recurrence within 5 years and > 5 years after curative nephrectomy, respectively. 6, 14 The risk factors responsible for LR were explored in patients without recurrence for ! 5 years postoperatively.
Pathologic, Immunohistochemistry, and Semiquantitative Evaluation
Pathologic Examination. All surgical specimens were available as FFPE blocks and were examined by staff pathologists using routine institutional procedures. The tumor stage and grade were reevaluated for the present study by 2 pathologists (T.K., M.Y.) using the 2004 World Health Organization classification 2 and the 2010 American Joint Committee on Cancer TNM staging system. 2 Capsular involvement (CAP-INV) of the tumor cells was defined as an expansive or infiltrative margin in accordance with the reported data. 15 A single representative block was selected for each patient, unless specified otherwise.
Immunohistochemistry. Antibodies against 4EBP1 (rabbit monoclonal antibody no. 9644; 1:2400 dilution), phosphorylated (p)-4EBP1 (T37/46; rabbit monoclonal antibody no. 2855; 1:800 dilution), and eIF4E (rabbit monoclonal antibody no. 2067; 1:200 dilution; all from Cell Signaling Technology Japan, Osaka, Japan) were used for immunohistochemistry (IHC). A standard previously reported staining procedure was used. 16 In brief, tissue sections (3 mm) obtained from the FFPE specimens were deparaffinized in xylene and rehydrated. Endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 15 minutes. The sections were incubated with primary antibodies overnight at 4 C in a moist chamber after the epitopes had been reactivated by autoclaving the sections in 10 mM citric buffer (pH 6.0) for eIF4E and p-4EBP1 (T37/46) and 10 mM Tris-EDTA (pH 9.0) for 4EBP1 at 120 C for 20 minutes. Detection was performed using the peroxidase method with 3,3 0 -diaminobenzidine in the presence of hydrogen peroxide. The sections were counterstained with hematoxylin for nuclear detection, dehydrated, and mounted as permanent histologic specimens. Negative controls consisted of sections in which the primary antibody had been replaced with noneimmune rabbit serum. Human breast cancer tissue served as a positive control (data not shown).
Semiquantitative Evaluation. IHC expression was semiquantitatively scored according to the mean area and staining intensity of positive cells on a microscope (Olympus BX50; Olympus Corporation, Tokyo, Japan). Positive staining was defined as e1030 -Clinical Genitourinary Cancer October 2018 4EBP1/eIF4E Activation in Clear Cell RCC 
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brown-colored staining of tumor cell cytoplasm or nucleus. The mean area of staining was evaluated as a staining area 50% (negative score) or > 50% (score, 1þ) of tumor cells and was graded as negative, weakly positive (score, 1þ), or strongly positive (score, 2þ; Figure 1A ). The IHC slides were independently evaluated by 2 of us (O.I. and S.N.), who were unaware of the clinical outcomes. Any discrepancy was resolved by consensus. The final scores were obtained by adding the area and intensity scores. High expression was defined as a strongly positive intensity with a > 50% staining area (final score, 3þ). Low protein expression was defined as a final score of 2þ.
Activation of the 4EBP1/eIF4E axis (signifying mTORC1 downstream signaling) was graded as weak, intermediate, or strong according to the combination of 4EBP1, p-4EBP1 (T37/46), and eIF4E expression in ccRCC tissues ( Figure 1B ). In the present study, we defined increases in the p-4EBP1 (T37/46)-to-4EBP1 and eIF4E-to-4EBP1 ratios to be aberrant hyperactivation of the 4EBP1/eIF4E axis, indicating enhanced protein synthesis for malignant behavior, including proliferation, invasion, and metastasis. 9 In 20 cases randomly selected from the study patients, the IHC grade of 4EBP1/eIF4E activation in ccRCC tissues was examined again using a different specimen from different FFPE blocks to determine the staining diversity and/or molecular heterogeneity within a tumor.
Prognostic Analysis of 4EBP1/eIF4E Activation in The Cancer Genome Atlas Database
We collected clinical data for the Kidney Renal Clear Cell Carcinoma (KIRC) from The Cancer Genome Atlas (TCGA; available at: https://cancergenome.nih.gov/) using the cBioPortal (available at: http://www.cbioportal.org/; accessed April 22, 2018) . 17 We also collected protein/phosphoprotein expression data (level 3) for the corresponding TCGA-KIRC patients from The Cancer Proteome Atlas (TCPA; available at: http://tcpaportal.org/tcpa/; accessed May 1, 2018). 18 The clinical details for each patient, including age, sex, TNM stage, Fuhrman grade, survival status, and follow-up duration were extracted from TCGA (n ¼ 538). Protein data for 4EBP1, p-4EBP1 (T37/46), p-4EBP1 (T70), and eIF4E were downloaded from TCPA. The TCGA-KIRC patients with distant metastasis at the initial diagnosis (n ¼ 54), neoadjuvant therapy (n ¼ 9), VHL disease (n ¼ 5; suspected on the pathology report), noneccRCC (n ¼ 2; suspected on the pathology report), synchronous bilateral RCC (n ¼ 1), or no available information on the disease-free interval (n ¼ 90), protein expression from TCPA (n ¼ 82), Fuhrman grade (n ¼ 4), or stage pT1 subcategory (n ¼ 4) were excluded from the present study (Supplemental Table 1 ; available in the online version). Thus, 287 TCGA-KIRC patients were eligible for the present analysis (Supplemental Table 2 ; available in the online version). The tumor stage was reallocated using the 2010 American Joint Committee on Cancer TNM staging system.
2
4EBP1 phosphorylation appears to occur at T37/46, T70, and S65 in this sequential order. 19 Phosphorylation of T70 seems to play the most important role in releasing 4EBP1 from eIF4E. 19 Just as for each protein of 4EBP1, p-4EBP1(T37/46), p-4EBP1 (T70), and eIF4E, we divided the TCGA patients into 2 groups according to expression level (high or low), using the following scores for each protein as the cutoff (z-score): À0.39, À0.49, À0.28, and À0.01, respectively. 4EBP1/eIF4E activation determined from the protein data was graded similarly to the IHC definition of the 4EBP1/eIF4E activation levels (Figure1B), with the exception that patients with high expression of both p-4EBP1 (T37/46) and p-4EBP1 (T70) were considered to have high p-4EBP1 expression ( Figure 2A ).
Statistical Analysis
Continuous variables were compared using the Student t test or Mann-Whitney U test. Comparisons between 2 categories were performed using cross-tabulation and Fisher's exact test or the c 2 test.
The Kaplan-Meier method with the log-rank test was used to analyze the survival outcomes. A log-rank test for trend was used to determine the trends among the Kaplan-Meier curves. The recurrence-free interval (RFI) was defined as the duration from the initial curative surgery to the first appearance of metastasis or local emergence of tumors at or adjacent to the primary site or the last follow-up examination in the absence of progressive disease. Variables that were significantly prognostic on univariate analyses were investigated using multivariate analysis. Variables predicting the RFI were assessed using Cox proportional hazards models, in which a stepwise regression method was used with a significance level of P .05 for exclusion of a variable on multivariate analysis. All P values were based on 2-sided statistical analysis. P < .05 was considered to indicate statistical significance. All analyses were performed using R statistical software, version 3.4.1 (available at: http://cran.rproject.org/).
Ethics
The Ethical Committee of the Yamagata University School of Medicine approved the study protocol (approval no. 15; approved May 9, 2017). The requirement for individual informed consent was waived owing to the retrospective design of the present study and because the anonymity of the participants was ensured. The present study was performed in accordance with the ethical standards in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Results
Overall Patient Characteristics
Consecutive patients (n ¼ 303) who had undergone curative surgery for localized ccRCC were included. The median follow-up duration was 7.53 years after radical (n ¼ 199) or partial (n ¼ 104) nephrectomy. The surgical approach was open for 191 and laparoscopic for 112 patients. The patient demographic data are summarized in Table 1 . Generally, more advanced conditions of pT stage (pT1a, pT1b, pT2, pT3, or pT4), regional lymph node involvement (pN0/Nx or pN1), Fuhrman grade (1, 2, 3, or 4), CAP-INV (expansive or infiltrative), and microvascular invasion (MVI; negative or positive) were observed in the recurrence group compared with the recurrence-free group. Although 4EBP1, p-4EBP1 (T37/46), and eIF4E protein expression was comparable between the recurrence-free and recurrence groups, the 4EBP1/ eIF4E axis was significantly hypoactivated in the patients without recurrence. Overall, only 2 patients with weak activation experienced recurrence (1 each with ER and LR). The axis activation levels were distributed at almost a similar frequency in pT stage, Fuhrman grade, pN status, MVI, and CAP-INV (P ¼ NS for all; Fisher's exact test; Figure 1C ).
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Clinical Genitourinary Cancer October 2018 -e1035 Figure 1 ; available in the online version). Moreover, the patients tended to experience recurrence after curative nephrectomy, because the 4EBP1/eIF4E axis became hyperactivated from weak to strong levels of 4EBP1/eIF4E activation (P ¼ .0041, log-rank test; P ¼ .0017, log-rank trend test; Figure 1D ). In the univariate Cox regression models, stage ! pT1b (vs. pT1a), stage pN1 (vs. pN0/Nx), Fuhrman grade 3/4 (vs. grade 1/2), infiltrative CAP-INV (vs. expansive), positive MVI (vs. negative), and intermediate or strong activation levels of 4EBP1/eIF4E axis (vs. weak) was significantly related to the risk of recurrence (Table 3) . On multivariate analysis, stage ! pT1b, Fuhrman grade 3/4, and intermediate to strong activation levels of the 4EBP1/eIF4E axis were independent predictive factors for overall recurrence (Table 3) .
For 20 patients, the 4EBP1/eIF4E activation levels were evaluated in 2 surgical specimens from different FFPE blocks per patient. The results demonstrated favorable concordance (75%) for the activation levels between the paired samples from the same patient (data not shown).
Clinicopathologic Features and Risk Factors for ER
The clinicopathologic characteristics of the patients with ER are listed in Table 4 . In line with the overall trend of the entire cohort (Tables 1 and 2 , Figure 1 , Supplemental Figure 1 ; available in the online version), the ER subgroup had more progressive and aggressive tumor stage, Fuhrman grade, nodal stage, CAP-INV, MVI, and 4EBP1/eIF4E activation level compared with the recurrence-free group (P < .05 for each, Fisher's exact test; Supplemental Table 3 ; available in the online version). The axis activation levels were similarly distributed according to pT stage, Fuhrman grade, pN stage, MVI, and CAP-INV (P ¼ .63, P ¼ .59, P ¼ .58, P ¼ .64, and P ¼ .84, respectively, Fisher's exact test; data not shown). The RFI on Kaplan-Meier plots was significantly shorter for the patients with stage ! pT1b, grade 3/4, pN1, infiltrative CAP-INV, positive MVI, and intermediate and strong activation levels of 4EBP1/eIF4E axis (P < .05 for each, log-rank test; Supplemental Figure 2 ; available in the online version). On univariate and multivariate Cox regression analyses, stage ! pT1b, grade 3/4, and intermediate and strong activation of 4EBP1/eIF4E axis were independent factors predictive of ER (Table 3) .
Clinicopathologic Features and Risk Factors for LR
No clinical recurrence had developed for > 5 years after the initial nephrectomy in 237 patients. The clinicopathologic characteristics of the patients with no recurrence for > 5 years (n ¼ 221; NR subgroup) and those with LR are listed in Table 4 . The median time from nephrectomy to LR was 9.0 years. The LR subgroup had a significantly greater stage and grade than did the NR subgroup; however, the differences in MVI status and 4EBP1/eIF4E activation level between the 2 subgroups were marginal for statistical significance. The frequency distribution of the activation levels was comparable for pT stage, Fuhrman grade, pN stage, MVI, and CAP-INV (P ¼ .83, P ¼ .54, P ¼ 1.00, P ¼ .61, and P ¼ .81, respectively, Fisher's exact test; data not shown). The Kaplan-Meier analysis revealed that the RFI for those with LR was significantly shorter for those with stage ! pT1b (vs. pT1a; P < .001, log-rank test; Supplemental Figure 3 ; available in the online version) and strong activation of the 4EBP1/eIF4E axis (vs. weak; P ¼ .0048, log-rank test with Holm adjustment; Figure 1D ). The results of univariate and multivariate Cox analyses are listed in Table 3 , with stage ! pT1b (vs. pT1a) and strong activation of the 4EBP1/eIF4E axis (vs. weak/intermediate) independent factors predictive of LR. In the Cox analyses, we set weak/intermediate activation levels as the reference to the strong level, because the Kaplan-Meier curves for the weak and intermediate levels crossed-over at w15 years after surgery ( Figure 1E) . Also, only a small number of LR patients had weak (n ¼ 1) or intermediate (n ¼ 6) activation levels, leading to insufficient power for statistical analysis ( Table 4 ).
The LR subgroup had a significantly younger age, lower pT stage, and Fuhrman grade compared with the ER subgroup ( Table 4 ). The metastatic profiles at recurrence differed significantly between the ER and LR subgroups (Table 4 ). OS after recurrence was significantly better for the LR subgroup than for the ER subgroup (median, 11.2 and 4.07 years, respectively; P ¼ .046, log-rank test; Supplemental Figure 4 ; available in the online version).
Prognostic Relevance of 4EBP1/eIF4E Activation in TCGA-KIRC Data Sets
Overall TCGA Patient Characteristics. The downloaded TCGA data for patients with nonmetastatic ccRCC (n ¼ 287; 193 men, 94 women; mean age, 59.0 years) were analyzed. The clinicopathologic features and profiles of the 4EBP1/eIF4E activation are presented in Table 1 . Postoperatively, 219 patients remained disease-free and 68 
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Clinical Genitourinary Cancer October 2018 -e1037 Figure 2B ). Kaplan-Meier survival analysis revealed that the RFI was significantly shorter for those with more advanced pT stage, pN stage, and Fuhrman grade ( Figure 2C ). Greater activation of the 4EBP1/eIF4E axis was significantly related to a greater incidence of recurrence (P ¼ .013, log-rank test; P ¼ .012, log-rank test for trend; Figure 2D ). On univariate and multivariate Cox analysis, stage ! pT1b, stage pN1, Fuhrman grade 3/4, and intermediate to strong activation of the axis were independent factors predicting for recurrence in TCGA patients with localized ccRCC (Table 3) .
Clinicopathologic Features and Risk Factors for ER and LR in TCGA Patients. Of the TCGA patients, 57 and 11 developed ER and LR, respectively ( Table 5 ). The ER-TCGA patients were older and had more progressive and aggressive T stage, N stage, Fuhrman grade, and 4EBP1/eIF4E activation level compared with those without recurrence (P < .05 for each, Fisher's exact test; Supplemental Table 3 ; available in the online version). Similarly, the LR-TCGA patients had a higher tumor grade and higher activation level of the 4EBP1/eIF4E axis; however, the pT stage did not differ between the recurrence-free (> 5 years) and LR-TCGA patients (Table 5) .
For the ER patients, the RFI on Kaplan-Meier plots was significantly shorter for those with stage ! pT1b (vs. pT1a), grade 3/4 (vs. grade 1/2), stage pN1 (vs. pN0/Nx), and intermediate to strong activation of the 4EBP1/eIF4E axis (vs. weak; P < .05 for each, logrank test; Supplemental Figure 5 ; available in the online version). In the univariate and multivariate Cox models, older age, stage ! pT1b, grade 3/4, and intermediate to strong activation of the 4EBP1/eIF4E axis were independent factors predictive of ER (Table 3) .
However, no patient in the recurrence-free (> 5 years) and LR-TCGA groups had stage pN1 (Table 5 , Supplemental Figure 6B ; available in the online version). In the for LR group, Fuhrman grade 3/4 shortened the RFI (P ¼ .034, log-rank test; Supplemental Figure 6C ; available in the online version), but pT stage (pT1a vs. ! pT1b) did not affect the RFI (P ¼ .54, log-rank test; Supplemental Figure 6A ; available in the online version). However, greater activation of the 4EBP1/eIF4E axis was significantly related to a greater incidence of LR (P ¼ .027, log-rank test; P ¼ .010, logrank test for trend; Figure 2E ). Univariate and multivariate Cox models revealed that a strong level of 4EBP1/eIF4E activation (vs. weak/intermediate) was a significant prognostic factor for LR (Table 3 ). In the Cox analyses for LR, the weak/intermediate activation levels were set as a reference to the strong level, because only a small number of LR events were found in the TCGA patients with weak (n ¼ 0) and intermediate (n ¼ 6) activation (Table 5) .
Discussion
To the best of our knowledge, we have shown for the first time that the activation level of the 4EBP1/eIF4E axis in localized ccRCC can contribute, not only to tumor recurrence, but also to the timing of the recurrence after curative nephrectomy. Our data have indicated that this activation can affect ER and LR events differently. Furthermore, the present findings using IHC were successfully validated by investigation of an external data set downloaded from TCGA and TCPA.
Campbell et al 12 reported that positive IHC expression of both p-4EBP1 (S65) and eIF4E in ccRCC tissues was related significantly to RFS after curative surgery for clinically confined ccRCC compared with the expression of only p-4EBP1 (S65) or eIF4E, or neither, although the influence of p-4EBP1 (S65)/eIF4E expression on LR and the assessment of total 4EBP1 levels was not described. 12 In a recent review, Musa et al 9 reported that no definitive conclusion can be drawn regarding the activation status of 4EBP1 without determining the p-4EBP1-to-total 4EBP1 and 4EBP1-to-eIF4E ratios in the tumor samples. Hence, in the present study, we graded 4EBP1/eIF4E activation using a combination of 4EBP1, p-4EBP1 (T37/46), and eIF4E IHC expression in ccRCC tissues and Skeletal muscle (n ¼ 1 and n ¼ 2 for ER and LR subgroups, respectively), pancreas and contralateral kidney (n ¼ 4 and n ¼ 1 for LR subgroup). g Follow-up duration was the interval from nephrectomy to the appearance of recurrence. h Mann-Whitney U test.
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Clinical Genitourinary Cancer October 2018 -e1039 considered the activation levels as an indicator of mRNA translation and protein biosynthesis rates in the individual tumor tissues. LR is a well-known oncologic feature of RCC. 6, 7 In the present study, similar to previous reports, 6 ,20 the incidence of LR was 5.3%
in the entire cohort and 34% in the patients with recurrence. Overall, the clinicopathologic characteristics of the patients with relapse mainly reflected those of the ER subgroup. In contrast, the LR subgroup were younger, had a lower pT stage and lower Fuhrman grade for the primary ccRCC, experienced metastatic recurrence at more varied sites (with less frequent pulmonary lesions), and had longer OS after recurrence compared with the ER subgroup. Stage pT1b or higher was an independent factor predicting for LR of ccRCC on multivariate analysis in the present study. These findings are consistent with those from previous studies, 6, 20, 21 suggesting that the present cohort was representative of patients with surgically treated localized ccRCC. LR-RCC has been reported to be less aggressive at initial surgery with more favorable outcomes after recurrence compared with ER-RCC. 14, 20, 21 On multivariate analyses, tumor diameter, pT stage, Fuhrman grade, tumor necrosis, sarcomatoid differentiation, lymphovascular invasion, and clinical symptoms are known independent markers of LR-RCC. 14, 20, 21 Differences in study design, data 14, 20 Patients with LR had a significantly longer progression-free survival and OS compared with those with ER. 14 However, the mechanisms by which LR patients retain apparently cancer-free status after primary surgery for several years until clinical recurrence have been poorly understood. Aberrant overexpression of key proteins via cap-dependent mRNA translation is known to be a requisite for malignant behavior (ie, proliferation, invasion, metastasis). 9, 25, 26 Apart from 4EBP1, eIF4E recognizes the 5 0 -7-methyl guanosine-capped structure of mRNAs and drives their translation. 9, 26 In our previous studies, we showed that glycogen synthase kinase-3 (GSK-3b), overexpressed in human RCC in most cases (92%), positively regulates the proliferation, survival, and antiapoptosis of RCC cells. 27 We recently demonstrated that GSK-3b directly phosphorylates 4EBP1 at T37/46, T70, and S65 and activates mTORC1 downstream signaling to enhance protein synthesis and cell proliferation in RCC cells, independent of mTORC1 activity. 28 However, mTORC1 (by phosphorylating 4EBP1) is generally considered a main regulator of the 4EBP1/eIF4E axis. 9, 29 Phosphorylation of 4EBP1 in an mTORC1-independent fashion has been found to sufficiently dissociate eIF4E from 4EBP1 binding. 29 GSK-3b might directly regulate upstream activation levels of the 4EBP1/eIF4E axis independently of mTORC1, affecting RCC viability and, consequently, affect the timing of clinical recurrence.
To the best of our knowledge, however, metabolic remodeling comprehensively contributes to a recurrent pattern in ccRCC that correlates with the tumor stage and severity. 30, 31 It has been demonstrated that the remodeling results from numerous alterations in genes controlling cellular oxygen sensing (eg, VHL inactivation, TCEB1 mutations), SWI/SNF (switch/sucrose nonfermentable) chromatin remodeling complex, the PI3K/Akt/mTOR signaling pathway, the KEAP1-NRF2-CUL3 apparatus, p53-related pathways, mRNA processing, downregulation of genes involved in the TCA (tricarboxylic acid) cycle, decreased AMPK (AMP-activated protein kinase) and PTEN (phosphatase and tensin homolog) protein levels, upregulation of the pentose phosphate pathway and glutamine transporter genes, increased acetyleco-enzyme A carboxylase protein, and altered promoter methylation of miR-21 and GRB10. 30, 31 These alterations in genes and proteins and, consequently, various signaling pathways could regulate tumor behavior and prognosis in an mTORC1-dependent and -independent fashion. 30, 31 Alternatively, differences between ER and LR could be ascribed to immunologic and inflammatory responses to RCC. 25 A shorter RFI after curative surgery has been shown in RCC patients with intratumoral neutrophils, a high neutrophil-to-lymphocyte ratio, and positive C-reactive protein in the peripheral blood. 20, 24, 32 Sejima et al 33 demonstrated that negative expression of the Fas ligand on RCC cells and a low neutrophil-to-lymphocyte ratio in peripheral blood were significantly related with LR but not with ER, suggesting a possible involvement of stronger host immune activity with LR than with ER.
Our study had some limitations. First, ccRCC is a heterogeneous tumor. 34 Because we analyzed 1 FFPE tumor block per patient in most cases, we could not account for heterogeneity in gene expression and intracellular signaling. 34 Second, the study patients were collected at a single tertiary center. Third, our study was retrospective. Fourth, we could not exclude the effects of the patients' comorbidities (eg, hypertension and obesity) and smoking habits on the prognostic outcomes owing to missing data. 2 Fifth, we could not evaluate host immune reactions because of incomplete laboratory data sets. Finally, in the present study, we could not investigate ER and LR events of ccRCC from the genomic aspect. Molecular subtypes of ccRCC have been correlated with OS, response rate, and progression-free survival during therapy with the angiogenesis inhibitors sunitinib and pazopanib and the prediction of RCC patients for ER after metastasectomy. [35] [36] [37] [38] Therefore, prospective and larger size studies that included genomic data are needed to confirm the present findings in the future.
Conclusion
Our retrospective analysis of clinicopathologic factors and intracellular activation levels of the 4EBP1/eIF4E axis to predict for postoperative recurrence in patients with localized ccRCC suggests that the activation levels of the 4EBP1/eIF4E axis in ccRCC tissues could have differential effects on the timing of recurrence. In a future study, these findings should be validated to discriminate between patients at high risk of ER and LR and to establish an optimal postoperative follow-up schedule for patients treated with curative surgery for nonmetastatic RCC.
Clinical Practice Points
Approximately 30% of nonmetastatic RCC patients curatively treated with nephrectomy will experience tumor recurrence, in most cases, as distant metastasis. LR (> 5 years) after curative resection is a well-known event for RCC (range, 6%-12%). It has been reported that tumor diameter, pT stage, Fuhrman grade, coagulative necrosis, sarcomatoid differentiation, lymphovascular invasion, and clinical symptoms are independent factors for LR-RCC; however, these factors have also been observed in ER-RCC. The mechanisms by which LR patients retain an apparently cancer-free status for several years after primary surgery until clinical recurrence are poorly understood. The present study has demonstrated that activation level of the 4EBP1/eIF4E axis in localized ccRCC might contribute, not only to tumor recurrence, but also to the timing of recurrence after curative nephrectomy. Strong activation of the axis was identified as an independent predictor for LR, with only 2 patients with weak activation developed recurrence (1 each with ER and LR). Our data indicate that this activation might affect ER and LR events differently. These findings could be relevant for discriminating between patients at high risk of ER and LR, leading to development of an optimal postoperative follow-up schedule for patients treated with curative surgery for nonmetastatic RCC.
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Metastatic RCC at initial diagnosis TCGA-B0-4843
Missing information on disease-free survival TCGA-B0-4844
Metastatic RCC at initial diagnosis TCGA-B0-4845
Metastatic RCC at initial diagnosis TCGA-B0-4846
Metastatic RCC at initial diagnosis TCGA-B0-4847
Missing information on disease-free survival TCGA-B0-4945
Missing information on disease-free survival TCGA-B0-5075
Missing information on disease-free survival TCGA-B0-5077
Missing information on disease-free survival TCGA-B0-5080
Metastatic RCC at initial diagnosis TCGA-B0-5083
Lack of protein data in TCGA and TCPA TCGA-B0-5084
Metastatic RCC at initial diagnosis TCGA-B0-5085
Missing information on disease-free survival TCGA-B0-5088
Missing information on disease-free survival TCGA-B0-5092
Missing information on disease-free survival TCGA-B0-5094
Metastatic RCC at initial diagnosis TCGA-B0-5095
Missing information on disease-free survival TCGA-B0-5096
Missing information on Fuhrman grade TCGA-B0-5098
Missing information on disease-free survival TCGA-B0-5099
Missing information on disease-free survival TCGA-B0-5104
Missing information on disease-free survival TCGA-B0-5106
Missing information on disease-free survival TCGA-B0-5107
Metastatic RCC at initial diagnosis TCGA-B0-5115
Metastatic RCC at initial diagnosis 4EBP1/eIF4E Activation in Clear Cell RCC
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Supplemental Missing information on disease-free survival TCGA-CJ-6031
Lack of protein data in TCPA TCGA-CJ-6033
Metastatic RCC at initial diagnosis TCGA-CW-5580
Missing information on disease-free survival TCGA-CW-5585
Metastatic RCC at initial diagnosis TCGA-CW-5590
Metastatic RCC at initial diagnosis TCGA-CW-5591
Metastatic RCC at initial diagnosis TCGA-CW-6087
Missing information on disease-free survival TCGA-CZ-4854
Missing information on disease-free survival TCGA-CZ-4857
Metastatic RCC at initial diagnosis TCGA-CZ-4860
Missing information on disease-free survival TCGA-CZ-4861
Missing information on disease-free survival TCGA-CZ-4864
Missing information on disease-free survival TCGA-CZ-4865
Missing information on disease-free survival TCGA-CZ-5453
Missing information on disease-free survival TCGA-CZ-5454
Metastatic RCC at initial diagnosis TCGA-CZ-5455
Missing information on disease-free survival TCGA-CZ-5460
Metastatic RCC at initial diagnosis TCGA-CZ-5461
Metastatic RCC at initial diagnosis TCGA-CZ-5462
Missing information on disease-free survival TCGA-CZ-5464
Metastatic RCC at initial diagnosis TCGA-CZ-5465
Missing information on disease-free survival TCGA-CZ-5468
Missing information on disease-free survival TCGA-CZ-5987
Metastatic RCC at initial diagnosis TCGA-DV-5565
Might have been a patient with VHL disease on pathology report at cBioPortal website Supplemental Neoadjuvant therapy TCGA-DV-5569
Might have been a patient with VHL disease on pathology report at cBioPortal website TCGA-DV-5573
Neoadjuvant therapy TCGA-DV-5574
Might have been a patient with VHL disease on pathology report at cBioPortal website TCGA-DV-5575
Might have been a patient with VHL disease on pathology report at cBioPortal website TCGA-DV-5576
Missing information on disease-free survival TCGA-DV-A4VX
Missing information on disease-free survival TCGA-DV-A4VZ
Lack of protein data in TCPA TCGA-DV-A4W0
Lack of protein data in TCGA and TCPA TCGA-G6-A5PC
Missing information on disease-free survival TCGA-G6-A8L6
Metastatic RCC at initial diagnosis TCGA-G6-A8L7
Lack of protein data in TCPA TCGA-G6-A8L8
Missing information on disease-free survival TCGA-GK-A6C7
Lack of protein data in TCPA TCGA-MM-A563
Lack of protein data in TCPA TCGA-MM-A564
Lack of protein data in TCPA TCGA-MM-A84U
A patient with synchronous bilateral RCC TCGA-MW-A4EC
Lack of protein data in TCPA TCGA-T7-A92I
Lack of protein data in TCGA and TCPA TCGA-DV-A4W0
Missing information on Fuhrman grade TCGA-3Z-A93Z
Missing information on Fuhrman grade 
